This has spurred the evaluation of the long-acting GLP-1 receptor agonist Exenatide, a peptide drug approved and efficacious in T2DM, as a new treatment approach in human PD clinical trials, where it has demonstrated promising efficacy [29–32]. This evidence concerns the gene GLP1R and Parkinson disease.